RNN: Rexahn Pharmaceuticals Inc Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, January 30, 11:13 AM Rexahn Pharmaceuticals (RNN +3.3%) moves up this morning after being initiated by analysts at Maxim with a Buy and a price target of $1.50 a share. The company specializes in oncology and CNS therapeutics, and has recently expanded its intellectual property around isoquinolinamine, a class of potent anti-cancer compounds, which provide potent anti-tumor activities in several human cancer cell lines, such as breast, prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma. Comment! [Healthcare, On the Move]
Tuesday, January 22, 11:48 AM Rexahn Pharmaceuticals (RNN +4.9%) trades higher today after saying it's appointed Dr. Peter D. Suzdak as its new chief executive officer. Dr. Suzdak succeeds Dr. Chang Ahn, who was recently appointed as the company's chief scientist. Dr. Ahn will also remain as chairman of the company's board of directors. Comment! [Healthcare, On the Move]
Wednesday, November 28, 2012, 4:47 PM Rexahn Pharmaceuticals (RNN) says it intends to offer shares of its common stock and warrants in an underwritten public offering. The shares are being offered as units, with no amount given at present. Earlier today the company announced it would be receiving additional funding from Teva Pharmaceutical (TEVA) for the development of its potential tumor treatment RX-3117. Burrill and Maxim Group are acting as joint book-running mangers for the offering. Comment! [Healthcare]
Wednesday, November 28, 2012, 12:53 PM Rexahn Pharmaceuticals (RNN +9%) trades higher after the company said that Teva Pharmaceutical (TEVA -0.6%) will provide an additional $750K in funding to the company. Pursuant to the terms of an earlier agreementl, TEVA will purchase RNN's common stock at 120% of its closing price on the last trading day preceding the closing. TEVA has also agreed to commit additional research funding for development of RX-3117, a potential treatment for solid tumors including colon, lung and pancreatic cancers, and will retain the right to file the Investigational New Drug application with the FDA. 2 Comments [Healthcare, On the Move]
Friday, July 6, 2012, 1:15 PM Off-radar microcap Rexahn Pharmaceuticals (RNN) is up another +16.6% today, having doubled since Monday's announcement that it's submitted an IND application to the FDA for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors. 4 Comments [Healthcare, On the Move]
Tuesday, February 8, 2011, 9:00 AM Premarket gainers: RHB +46%. KND +26%. CNXT +17%. XIDE +15%. SOMX +6%. CXZ +5%. CPST +5%. MT +5%. BYD +4%. MGM +4%. NTWK +4%. MOTR +4%. CCME +4%.
Losers: BR -12%. GLUU -7%. OLP -6%. TEVA -5%. RNN -5%. BBEP -5%. PPNT -5%. AVP -4%. KTOS -4%. Comment!
Thursday, December 2, 2010, 9:00 AM Premarket gainers: WBD +30%. RNN +22%. PSS +16%. ANF +8%. WTSLA +8%. S +8%. FNSR +6%. SGMO +5%. STP +4%.
Losers: SQNM -9%. ARO -9%. SEP -4%. AEO -4%. Comment!
Tuesday, October 19, 2010, 9:15 AM Premarket gainers: CTIC +14%. MEE +10%. PH +9%. RNN +7%.
Losers: INFN -33%. CWTR -29%. OGXI -15%. KCI -13%. BXC -11%. HT -7%. BKCC -7%. NVO -7%. VMW -7%. AIB -6%. ABK -5%. RIO -5%. ALU -5%. AAPL -5%. HL -4%. IBM -4%. RCL -4%. AUY -4%. ARMH -4%. WFT -4%. BHP -4%. SLW -4%. TOT -4%. Comment!
Thursday, September 2, 2010, 9:00 AM Premarket gainers: OREX +27%. BKC +21%. CRME +12%. RNN +12%. CERS +8%. CTIC +5%. WEN +4%. MPEL +4%.
Losers: PSS -6%. Comment!
Wednesday, June 23, 2010, 9:05 AM Premarket gainers: JBL +11%. KMX +10%. RAD +10%. RNN +7%. SAY +5%. CTIC +4%. LYG +4%. ACAS +4%. VG +4%.
Losers: RGLD -5%. Comment!
Thursday, May 13, 2010, 9:00 AM Premarket gainers: SY +15%. PUDA +15%. TGB +10%. NNA +9%. WFMI +6%. DVAX +6%. RNN +5%. IMMU +4%. EBAY +4%. CLNE +4%.
Losers: RAS -9%. RPT -8%. AGEN -5%. VNR -5%. IRE -4%. WES -4%. Comment!
Wednesday, April 28, 2010, 9:10 AM Premarket gainers: NBG +10%. TSFG +8%. CIIC +7%. NVAX +8%. BCRX +7%. RFMD +6%. TLAB +6%. ACAS +6%. RNN +6%. YRCW +5%. ABK +5%. PCBC +5%. MPEL +5%. ERIC +5%. UAUA +4%. LCC +4%. DCTH +4%. TMO +4%. CRBC +4%. CMCSA +4%. GT +4%. CHU +4%. SQNM +4%.
Losers: BWLD -19%. RHI -11%. CNXT -10%. FBC -10%. PFCB -4%. 1 Comment
Monday, April 19, 2010, 9:00 AM Premarket gainers: CRN +35%. YMI +9%. CTIC +5%. IMMU +4%. SQNM +4%.
Losers: RNN -13%. TSFG -7%. SPF -7%. PALM -6%. FRE -5%. FNM -5%. Comment!
Thursday, April 15, 2010, 9:00 AM Premarket gainers: ME +38%. ANDS +25%. AEZS +20%. IDIX +16%. TSFG +15%. IOC +9%. PPHM +10%. ABK +8%. CPBY +8%. IMGN +8%. RNN +7%. SIRI +6%. XOM +6%. JOEZ +6%. END +5%. YRCW +5%. AVNR +5%. UPS +4%. MDVN +4%. SOLR +4%. SGY +4%.
Losers: SNTS -34%. TITN -13%. NEP -9%. SMOD -6%. REVU -6%. MAC -6%. MGM -6%. AGEN -4%. APA -4%. BPOP -4%. Comment!
Wednesday, April 14, 2010, 9:00 AM Premarket gainers: KLIC +21%. ABK +19%. CRXX +17%. RNN +9%. HOTT +8%. SIRI +7%. PAL +6%. AIB +6%. TLAB +5%. FNM +6%. INTC +4%. AMD +4%. ERIC +4%. MBI +4%. VVUS +4%. PALM +4%.
Losers: NBG -4%. Comment!
Monday, April 12, 2010, 9:20 AM Premarket gainers: DCP +48%. WEL +26%. DBTK +15%. ABK +15%. RNN +14%. MIR +163%. RRI +13%. PALM +8%. FCEL +7%. KERX +6%. AVNR +6%. ICOC +6%. CPKI +5%. JUEZ +5%. CIEN +5%. DYN +4%. UBS +4%.
Losers: CLNE -7%. Comment!

RNN Rexahn Pharmaceuticals Inc

RNN

Rexahn Pharmaceuticals Inc